NCCN Expands Pediatric Cancer Guidelines with Focus on Rhabdomyosarcoma

Event summary

  • NCCN published new guidelines for Pediatric Soft Tissue Sarcomas on February 17, 2026, focusing on rhabdomyosarcoma (RMS).
  • This is the 7th pediatric cancer guideline, expanding NCCN's library to 91 topics in cancer care.
  • RMS represents nearly 5% of all childhood cancers and is the most common soft tissue sarcoma in people under 20.
  • The guidelines emphasize tailored treatments balancing cure goals with minimizing side effects for young patients.

The big picture

The new guidelines highlight the fundamental biological differences between pediatric and adult cancers, emphasizing the need for specialized treatment protocols. This expansion of NCCN's guidelines library reflects the growing recognition of pediatric oncology as a distinct field requiring targeted approaches. The focus on minimizing long-term side effects aligns with broader trends in precision medicine and patient-centered care.

What we're watching

Adoption Pace
How quickly global cancer care providers will integrate these specialized guidelines into practice.
Outcome Impact
Whether the tailored treatment approaches will demonstrably improve cure rates and reduce long-term side effects in pediatric RMS patients.
Research Focus
The pace at which new genetic and clinical insights will be incorporated into future guideline updates.

Related topics

Oncology